Tg Therapeutics (TGTX) Net Income towards Common Stockholders: 2016-2025
Historic Net Income towards Common Stockholders for Tg Therapeutics (TGTX) over the last 10 years, with Sep 2025 value amounting to $390.9 million.
- Tg Therapeutics' Net Income towards Common Stockholders rose 10006.23% to $390.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $447.5 million, marking a year-over-year increase of 3212.81%. This contributed to the annual value of $23.4 million for FY2024, which is 84.52% up from last year.
- Tg Therapeutics' Net Income towards Common Stockholders amounted to $390.9 million in Q3 2025, which was up 1,286.84% from $28.2 million recorded in Q2 2025.
- Tg Therapeutics' Net Income towards Common Stockholders' 5-year high stood at $390.9 million during Q3 2025, with a 5-year trough of -$94.0 million in Q4 2021.
- Over the past 3 years, Tg Therapeutics' median Net Income towards Common Stockholders value was $5.1 million (recorded in 2025), while the average stood at $41.8 million.
- Per our database at Business Quant, Tg Therapeutics' Net Income towards Common Stockholders slumped by 96.60% in 2024 and then skyrocketed by 10,006.23% in 2025.
- Tg Therapeutics' Net Income towards Common Stockholders (Quarterly) stood at -$94.0 million in 2021, then rose by 14.49% to -$80.4 million in 2022, then soared by 82.07% to -$14.4 million in 2023, then skyrocketed by 261.92% to $23.3 million in 2024, then soared by 10,006.23% to $390.9 million in 2025.
- Its Net Income towards Common Stockholders was $390.9 million in Q3 2025, compared to $28.2 million in Q2 2025 and $5.1 million in Q1 2025.